In this real-world Medicare claims analysis, researchers examined patients with newly diagnosed Parkinson’s disease psychosis (PDP) who started pimavanserin within 6 months of diagnosis and remained on monotherapy for at least 6 months. Among 694 eligible patients, early pimavanserin initiation was associated with lower healthcare resource utilization in the following 6 months compared with the 6 months before treatment. Reductions were seen in all-cause inpatient hospitalizations, emergency department (ED) visits, outpatient visits, and office visits, with especially notable declines in ED visits and short-term hospital stays. Psychiatric-related utilization also fell, including fewer psychiatric-related inpatient hospitalizations, ED visits, outpatient visits, and office visits.
The authors suggest these findings support the potential value of starting pimavanserin earlier in the course of PDP, when hallucinations and delusions may still be driving frequent healthcare encounters and added burden for patients and caregivers. They note that the pattern of reduced utilization may reflect better symptom control and point to pimavanserin’s possible role as a first-line treatment option. They also acknowledge that this was an observational pre-post claims analysis without a comparator group, so the results should be interpreted as descriptive associations rather than proof of causation. Overall, the study adds real-world evidence that earlier pimavanserin use may help reduce the healthcare burden associated with PDP and supports further research on how timing of treatment initiation affects outcomes.
Bottom of Form
Reference: Rashid N, Rajagopalan K, Gopal D, Chrones L, Doshi D. Impact of Early Treatment with Pimavanserin on Healthcare Resource Utilization Among Newly Diagnosed Patients with Parkinson’s Disease Psychosis: A Pre-Post Medicare Claims Database Analysis. J Health Econ Outcomes Res. 2026 Jan 23;13(1):1-9. doi: 10.36469/001c.154805.
